Price movement over the last 24 hours
AdaptHealth Corp vs Church & Dwight Co., Inc. — how do they compare? AdaptHealth Corp trades at $10.06 (market cap $1.38B), while Church & Dwight Co., Inc. trades at $97 (market cap $23.45B). The key difference: Church & Dwight Co., Inc. is far larger — about 17× AdaptHealth Corp's market cap, and Church & Dwight Co., Inc. pays a 1.41% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | CHD | |
|---|---|---|
Market Cap | $1.38B | $23.45B |
Sector | Health | Consumer Staples |
52-Week High | $13.38 | $105.26 |
52-Week Low | $8.68 | $81.60 |
Enterprise Value | $3.33B | $25.15B |
Dividend Yield | — | 1.41% |
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.
The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.
Church & Dwight (CHD) trades at $98.95, up 0.35% with a bullish technical signal from moving averages. The company reported three consecutive quarterly EPS beats, with Q1 2026 adjusted EPS of $0.95 beating the $0.93 estimate (Zacks Investment Research, 2026-05-01). Recent acquisition of Miss Mouth's brand for $325 million strengthens its fabric care portfolio. Valuation metrics show a P/E of 32.43 and ROE of 16.78%, indicating premium pricing but strong profitability.
Outlook remains positive with 53% analyst buy ratings and a $100.50 consensus target, though net cash flow turned negative in 2025. Risks include cost pressures impacting margins, as seen in Q1 profit slippage (WSJ, 2026-05-01), and high debt levels. The stock offers growth potential through organic sales expansion and strategic acquisitions, but investors should monitor margin sustainability and competitive dynamics in consumer staples.
Trailing returns across standard periods
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →